Industry sponsored studies twice as likely to have positive conclusions about costsBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7422.1006-b (Published 30 October 2003) Cite this as: BMJ 2003;327:1006
- Roger Dobson
Researchers have warned of the risk of sponsorship bias in health economic studies in the field of cancer.
Industry sponsored studies were twice as likely to be cost minimisation analyses, which compare equally effective treatments on the basis of costs. The industry studies were 2.5 times …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial